Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response
NCT00103545 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 36
Last updated 2006-10-02
Summary
The purpose of this study is to use an immunologic approach following the treatment for recurrent disease in patients with ovarian, fallopian tube, or peritoneal cancer.
Conditions
- Ovarian Cancer
- Fallopian Tube Neoplasms
- Peritoneal Neoplasms
Interventions
- BIOLOGICAL
-
ACA 125
Sponsors & Collaborators
-
AGO Study Group
lead OTHER
Principal Investigators
-
Jacobus Pfisterer, Prof. Dr. · AGO Study Group
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 0 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2003-07-31
- Completion
- 2004-08-31
Countries
- Germany
Study Locations
More Related Trials
-
Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT00004064 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients
NCT00418574 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Combination Chemotherapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer
NCT00031954 ·Status: COMPLETED ·Phase: PHASE2
-
Carboxyamidotriazole in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
NCT00019461 ·Status: COMPLETED ·Phase: PHASE2
-
Ovarian Cancer Risk Estimation in Patients With Pelvic Mass
NCT00987649 ·Status: COMPLETED
-
Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer
NCT00660101 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer
NCT02125513 ·Status: UNKNOWN ·Phase: PHASE2
-
Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer
NCT03249142 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer
NCT00466986 ·Status: COMPLETED ·Phase: PHASE2
-
AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma
NCT03668340 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT00753480 ·Status: SUSPENDED ·Phase: PHASE1
-
Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT02520154 ·Status: COMPLETED ·Phase: PHASE2
-
Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer
NCT05080556 ·Status: RECRUITING ·Phase: PHASE2
-
Efficacy and Safety of AK104 (PD-1/CTLA-4 Bispecial Antibody) Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer
NCT06542549 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Intraperitoneal Infusion of ex Vivo-cultured Allogeneic NK Cells in Recurrent Ovarian Carcinoma Patients
NCT03539406 ·Status: COMPLETED ·Phase: PHASE1
-
OveRcoming immunosupprEssion aNd rebAlancing the Immune reSponSe in ovAriaN CancEr Study
NCT06611072 ·Status: RECRUITING ·Phase: NA
-
Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
NCT01381861 ·Status: COMPLETED ·Phase: PHASE2
-
AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer
NCT05617755 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Blood Test for Ovarian Cancer Associated Antibodies (CAAb)
NCT00327925 ·Status: UNKNOWN
-
A Study of ABT-263 as Single Agent in Women With Platinum Resistant/Refractory Recurrent Ovarian Cancer
NCT02591095 ·Status: COMPLETED ·Phase: PHASE2
-
Genomic Profiling of the Residual Disease of Advanced-stage Ovarian Cancer After Neoadjuvant Chemotherapy
NCT03491033 ·Status: COMPLETED
-
Risk of Ovarian Cancer in Patients With a Pelvic Mass
NCT00315692 ·Status: COMPLETED
-
CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifen
NCT00305838 ·Status: UNKNOWN ·Phase: PHASE2
-
Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer
NCT00003385 ·Status: COMPLETED ·Phase: PHASE1
-
Adoptive T Cell Therapy in Patients With Recurrent Ovarian Cancer
NCT04072263 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2